Skip to main content
Erschienen in: Drugs 4/2015

01.03.2015 | Adis Drug Evaluation

Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout

verfasst von: James E. Frampton

Erschienen in: Drugs | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Febuxostat (Adenuric®, Uloric®, Feburic®) is an orally-active, potent, non-purine, selective xanthine oxidase inhibitor. In the EU, it is indicated in adults for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred. Unlike allopurinol, the prototypical xanthine oxidase inhibitor that is the cornerstone therapy for chronic gout, febuxostat does not require dosage adjustment in patients with mild or moderate renal impairment. In randomized, double-blind studies, 6–12 months’ treatment with febuxostat at dosages approved for use in the EU (80 and 120 mg/day) was significantly more effective in lowering serum uric acid (sUA) levels in patients with hyperuricaemia and gout than allopurinol at dosages commonly prescribed in practice (100–300 mg/day); febuxostat demonstrated greater urate-lowering efficacy than allopurinol in patients with renal impairment. In open-label extension studies, 3–5 years’ treatment with febuxostat maintained a target sUA level of <6.0 mg/dL in most patients; sustained reduction in sUA level was associated with near elimination of gout flares and improved tophus status. Febuxostat therapy was generally well tolerated during clinical development; frequently reported adverse events included liver function abnormalities, diarrhoea and rash. Cardiovascular (CV) events were the most common serious adverse events; the comparative safety of febuxostat and allopurinol is being examined further in large, ongoing trials in patients with gout who already have, or are at risk of developing, CV disease. In conclusion, febuxostat is a well established antihyperuricaemic agent that provides an effective alternative to allopurinol for the management of chronic gout.
Literatur
4.
Zurück zum Zitat Becker MA, Ruoff GE. What do I need to know about gout? J Fam Pract. 2010;59(6 Suppl):S1–8.PubMed Becker MA, Ruoff GE. What do I need to know about gout? J Fam Pract. 2010;59(6 Suppl):S1–8.PubMed
5.
Zurück zum Zitat Ye P, Yang S, Zhang W, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35(2):180–9.CrossRefPubMed Ye P, Yang S, Zhang W, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35(2):180–9.CrossRefPubMed
6.
Zurück zum Zitat Grewal HK, Martinez JR, Espinoza LR. Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol. 2014;10(5):747–58.CrossRefPubMed Grewal HK, Martinez JR, Espinoza LR. Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol. 2014;10(5):747–58.CrossRefPubMed
7.
Zurück zum Zitat Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10(5):271–83.CrossRefPubMed Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10(5):271–83.CrossRefPubMed
8.
Zurück zum Zitat Cassagnol M, Saad M. Pharmacologic management of gout. US Pharm. 2013;38(3):22–6. Cassagnol M, Saad M. Pharmacologic management of gout. US Pharm. 2013;38(3):22–6.
9.
Zurück zum Zitat Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout—what are the treatment options? Expert Opin Pharmacother. 2009;10(8):1319–28.CrossRefPubMed Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout—what are the treatment options? Expert Opin Pharmacother. 2009;10(8):1319–28.CrossRefPubMed
10.
11.
Zurück zum Zitat Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.CrossRefPubMedCentralPubMed Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46.CrossRef Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46.CrossRef
13.
Zurück zum Zitat Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82.CrossRefPubMed Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273–82.CrossRefPubMed
16.
Zurück zum Zitat Teijin Pharma Limited. Feburic®: full prescribing information. Tokyo: Teijin Pharma Limited; 2011. Teijin Pharma Limited. Feburic®: full prescribing information. Tokyo: Teijin Pharma Limited; 2011.
17.
Zurück zum Zitat Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31(11):2503–18.CrossRefPubMed Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31(11):2503–18.CrossRefPubMed
18.
Zurück zum Zitat Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209–20.PubMedCentralPubMed Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag. 2008;4(6):1209–20.PubMedCentralPubMed
19.
Zurück zum Zitat Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87–114.CrossRefPubMedCentralPubMed Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87–114.CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22–34.CrossRefPubMed Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22–34.CrossRefPubMed
21.
22.
Zurück zum Zitat Saag KG, Becker MA, Whelton A, et al. Effect of febuxostat on serum urate levels in gout subjects with hyperuricemia and moderate-to-severe renal impairment: a randomized controlled trial [abstract no. 1178]. Arthritis Rheum. 2013;65:S498–9. Saag KG, Becker MA, Whelton A, et al. Effect of febuxostat on serum urate levels in gout subjects with hyperuricemia and moderate-to-severe renal impairment: a randomized controlled trial [abstract no. 1178]. Arthritis Rheum. 2013;65:S498–9.
23.
Zurück zum Zitat Tsai M, Wu J-T, Gunawardhana L, et al. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. Int J Clin Pharmacol Ther. 2012;50(5):331–7.CrossRefPubMed Tsai M, Wu J-T, Gunawardhana L, et al. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. Int J Clin Pharmacol Ther. 2012;50(5):331–7.CrossRefPubMed
24.
Zurück zum Zitat Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916–23.CrossRefPubMed Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916–23.CrossRefPubMed
25.
Zurück zum Zitat Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Care Res. 2008;59(11):1540–8.CrossRef Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Care Res. 2008;59(11):1540–8.CrossRef
26.
Zurück zum Zitat Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.CrossRefPubMed Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.CrossRefPubMed
27.
Zurück zum Zitat Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S19–26.CrossRefPubMed Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S19–26.CrossRefPubMed
28.
Zurück zum Zitat Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S35–43.CrossRefPubMed Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S35–43.CrossRefPubMed
29.
Zurück zum Zitat Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13–8.CrossRefPubMed Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13–8.CrossRefPubMed
30.
Zurück zum Zitat Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17(6):679–86.CrossRefPubMed Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17(6):679–86.CrossRefPubMed
31.
Zurück zum Zitat Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009;48:188–94.CrossRefPubMed Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009;48:188–94.CrossRefPubMed
33.
Zurück zum Zitat Becker MA, MacDonald PA, Hunt B, et al. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011–7.CrossRefPubMed Becker MA, MacDonald PA, Hunt B, et al. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1011–7.CrossRefPubMed
34.
Zurück zum Zitat Becker MA, MacDonald PA, Hunt BJ, et al. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013;15(11):1049–55.CrossRefPubMedCentralPubMed Becker MA, MacDonald PA, Hunt BJ, et al. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013;15(11):1049–55.CrossRefPubMedCentralPubMed
36.
Zurück zum Zitat Chohan S, Becker MA, MacDonald PA, et al. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res. 2012;64(2):256–61.CrossRef Chohan S, Becker MA, MacDonald PA, et al. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res. 2012;64(2):256–61.CrossRef
38.
Zurück zum Zitat Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386–97.CrossRefPubMed Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386–97.CrossRefPubMed
40.
Zurück zum Zitat Whelton A, MacDonald PA, Chefo S, et al. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106–14.CrossRefPubMed Whelton A, MacDonald PA, Chefo S, et al. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106–14.CrossRefPubMed
41.
Zurück zum Zitat Whelton A, MacDonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7–13.CrossRefPubMed Whelton A, MacDonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7–13.CrossRefPubMed
42.
Zurück zum Zitat Grassi D, Pontremoli R, Bocale R, et al. Therapeutic approaches to chronic hyperuricemia and gout. High Blood Press Cardiovasc Prev. 2014;21(4):243–50.CrossRefPubMed Grassi D, Pontremoli R, Bocale R, et al. Therapeutic approaches to chronic hyperuricemia and gout. High Blood Press Cardiovasc Prev. 2014;21(4):243–50.CrossRefPubMed
43.
Zurück zum Zitat Overman RA, Mandell BF, Deal CL. Use of uric lowering therapies within a large health care system. [abstract no. 1909]. Arthritis Rheum. 2012;64(Suppl 10):S811. Overman RA, Mandell BF, Deal CL. Use of uric lowering therapies within a large health care system. [abstract no. 1909]. Arthritis Rheum. 2012;64(Suppl 10):S811.
44.
Zurück zum Zitat Hatoum H, Khanna D, Lin S-J, et al. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65–75.CrossRefPubMed Hatoum H, Khanna D, Lin S-J, et al. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65–75.CrossRefPubMed
45.
Zurück zum Zitat Becker MA, Ye X, Akhras KS, et al. Comparing clinical characteristics and comorbidities of gout patients treated with allopurinol or febuxostat [abstract no. 1814]. Arthritis Rheum. 2012;64:S771–2. Becker MA, Ye X, Akhras KS, et al. Comparing clinical characteristics and comorbidities of gout patients treated with allopurinol or febuxostat [abstract no. 1814]. Arthritis Rheum. 2012;64:S771–2.
46.
Zurück zum Zitat Perez-Ruiz F, Herrero-Beites AM. Liver outcomes in gout patients treated with febuxostat and altered liver function tests [abstract no. 1987]. Arthritis Rheum. 2013;65:S847. Perez-Ruiz F, Herrero-Beites AM. Liver outcomes in gout patients treated with febuxostat and altered liver function tests [abstract no. 1987]. Arthritis Rheum. 2013;65:S847.
47.
Zurück zum Zitat Stamp LK. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol. 2014;26(2):162–8.CrossRefPubMed Stamp LK. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol. 2014;26(2):162–8.CrossRefPubMed
48.
Zurück zum Zitat MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354. doi:10.1136/bmjopen-2014-005354.CrossRefPubMedCentralPubMed MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354. doi:10.​1136/​bmjopen-2014-005354.CrossRefPubMedCentralPubMed
49.
Zurück zum Zitat White WB, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012;164(1):14–20.CrossRefPubMed White WB, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012;164(1):14–20.CrossRefPubMed
50.
Zurück zum Zitat Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014;15(5):453–63.PubMed Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014;15(5):453–63.PubMed
51.
Zurück zum Zitat Cuesta M, Perez Alcantara F, Brosa M. Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Spain [abstract no. PSY28]. Value Health. 2012;15(7):A513.CrossRef Cuesta M, Perez Alcantara F, Brosa M. Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Spain [abstract no. PSY28]. Value Health. 2012;15(7):A513.CrossRef
53.
Zurück zum Zitat Manara M, Bortoluzzi A, Favero M, et al. Italian Society of Rheumatology recommendations for the management of gout. Reumatismo. 2013;65(1):4–21.CrossRefPubMed Manara M, Bortoluzzi A, Favero M, et al. Italian Society of Rheumatology recommendations for the management of gout. Reumatismo. 2013;65(1):4–21.CrossRefPubMed
55.
Zurück zum Zitat Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleos Nucleot Nucleic Acids. 2004;23(8–9):1111–6.CrossRef Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleos Nucleot Nucleic Acids. 2004;23(8–9):1111–6.CrossRef
56.
Zurück zum Zitat Khosravan R, Grabowski B, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88–102.CrossRefPubMed Khosravan R, Grabowski B, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88–102.CrossRefPubMed
58.
Zurück zum Zitat Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328–35.CrossRefPubMedCentralPubMed Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328–35.CrossRefPubMedCentralPubMed
Metadaten
Titel
Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout
verfasst von
James E. Frampton
Publikationsdatum
01.03.2015
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 4/2015
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0360-7

Weitere Artikel der Ausgabe 4/2015

Drugs 4/2015 Zur Ausgabe